PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT 2.1 Preface 2.2 Preface 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE Market ecosystem Market characteristics Market segmentation analysis PART 04: MARKET SIZING Market definition Market sizing 2018 Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition PART 06: MARKET SEGMENTATION BY PRODUCT Market segmentation by product Comparison by product Chemotherapy - Market size and forecast 2018-2023 Targeted therapy - Market size and forecast 2018-2023 Market opportunity by product PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE Geographic segmentation Geographic comparison North America - Market size and forecast 2018-2023 Europe - Market size and forecast 2018-2023 Asia - Market size and forecast 2018-2023 ROW - Market size and forecast 2018-2023 Key leading countries Market opportunity PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES Market drivers Market challenges PART 11: MARKET TRENDS Increasing research grants for blood cancers Advent of novel therapies Special drug designations PART 12: VENDOR LANDSCAPE Overview Landscape disruption Competitive scenario PART 13: VENDOR ANALYSIS Vendors covered Vendor classification Market positioning of vendors AstraZeneca Plc F. Hoffmann-La Roche Ltd. Merck & Co., Inc. Mylan NV Pfizer Inc. PART 14: APPENDIX Research methodology List of abbreviations Definition of market positioning of vendors PART 15: EXPLORE TECHNAVIO   Exhibit 01: Product overview Exhibit 02: Global pharmaceuticals market Exhibit 03: Segments of global pharmaceuticals market Exhibit 04: Market characteristics Exhibit 05: Market segments Exhibit 06: Market definition - Inclusions and exclusions checklist Exhibit 07: Market size 2018 Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 09: Global market: Year-over-year growth 2019-2023 (%) Exhibit 10: Five forces analysis 2018 Exhibit 11: Five forces analysis 2023 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2018 Exhibit 18: Product - Market share 2018-2023 (%) Exhibit 19: Comparison by product Exhibit 20: Chemotherapy - Market size and forecast 2018-2023 ($ millions) Exhibit 21: Chemotherapy - Year-over-year growth 2019-2023 (%) Exhibit 22: Targeted therapy - Market size and forecast 2018-2023 ($ millions) Exhibit 23: Targeted therapy - Year-over-year growth 2019-2023 (%) Exhibit 24: Patient assistance programs Exhibit 25: Market opportunity by product Exhibit 26: Customer landscape Exhibit 27: Market share by geography 2018-2023 (%) Exhibit 28: Geographic comparison Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 30: North America - Year-over-year growth 2019-2023 (%) Exhibit 31: Top 3 countries in North America Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 33: Europe - Year-over-year growth 2019-2023 (%) Exhibit 34: Top 3 countries in Europe Exhibit 35: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 36: Proportion of geriatric population in Asia 2009 and 2018 Exhibit 37: Asia - Year-over-year growth 2019-2023 (%) Exhibit 38: Top 3 countries in Asia Exhibit 39: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 40: ROW - Year-over-year growth 2019-2023 (%) Exhibit 41: Top 3 countries in ROW Exhibit 42: Key leading countries Exhibit 43: Market opportunity Exhibit 44: Growth in geriatric population 2014-2018 (%) Exhibit 45: Side effects of chemotherapy drugs used for treatment of hairy cell leukemia Exhibit 46: Impact of drivers and challenges Exhibit 47: Drug designations Exhibit 48: Vendor landscape Exhibit 49: Landscape disruption Exhibit 50: Vendors covered Exhibit 51: Vendor classification Exhibit 52: Market positioning of vendors Exhibit 53: AstraZeneca Plc - Vendor overview Exhibit 54: AstraZeneca Plc - Business segments Exhibit 55: AstraZeneca Plc - Organizational developments Exhibit 56: AstraZeneca Plc - Geographic focus Exhibit 57: AstraZeneca Plc - Key offerings Exhibit 58: AstraZeneca Plc - Key customers Exhibit 59: F. Hoffmann-La Roche Ltd. - Vendor overview Exhibit 60: F. Hoffmann-La Roche Ltd. - Product segments Exhibit 61: F. Hoffmann-La Roche Ltd. - Organizational developments Exhibit 62: F. Hoffmann-La Roche Ltd. - Geographic focus Exhibit 63: F. Hoffmann-La Roche Ltd. - Segment focus Exhibit 64: F. Hoffmann-La Roche Ltd. - Key offerings Exhibit 65: F. Hoffmann-La Roche Ltd. - Key customers Exhibit 66: Merck & Co. Inc. - Vendor overview Exhibit 67: Merck & Co. Inc. - Business segments Exhibit 68: Merck & Co. Inc. - Organizational developments Exhibit 69: Merck & Co. Inc. - Geographic focus Exhibit 70: Merck & Co. Inc. - Segment focus Exhibit 71: Merck & Co. Inc. - Key offerings Exhibit 72: Merck & Co. Inc. - Key customers Exhibit 73: Mylan NV - Vendor overview Exhibit 74: Mylan NV - Product segments Exhibit 75: Mylan NV - Organizational developments Exhibit 76: Mylan NV - Geographic focus Exhibit 77: Mylan NV - Segment focus Exhibit 78: Mylan NV - Key offerings Exhibit 79: Mylan NV - Key customers Exhibit 80: Pfizer Inc. - Vendor overview Exhibit 81: Pfizer Inc. - Business segments Exhibit 82: Pfizer Inc. - Organizational developments Exhibit 83: Pfizer Inc. - Geographic focus Exhibit 84: Pfizer Inc. - Segment focus Exhibit 85: Pfizer Inc. - Key offerings Exhibit 86: Pfizer Inc. - Key customers Exhibit 87: Validation techniques employed for market sizing Exhibit 88: Definition of market positioning of vendors    

AstraZeneca Plc, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Mylan NV, and Pfizer Inc.